ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
9.12
-0.09 (-0.98%)
At close: Oct 7, 2026, 4:00 PM EDT
9.22
+0.10 (1.10%)
After-hours: Oct 7, 2026, 7:30 PM EDT
ProMIS Neurosciences Employees
As of December 31, 2025, ProMIS Neurosciences had 11 total employees, including 10 full-time and 1 part-time employees. The number of employees increased by 3 or 37.50% compared to the previous year. That makes ProMIS Neurosciences the world's 39,888th largest employer and 6,031st in the United States.
Employees
11
Change (1Y)
3
Growth (1Y)
37.50%
Revenue / Employee
n/a
Profits / Employee
-$3,838,931
Market Cap
81.79M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 11 | 3 | 37.50% | 10 | 1 |
| Dec 31, 2024 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2023 | 7 | 0 | - | 6 | 1 |
| Dec 31, 2022 | 7 | 1 | 16.67% | 6 | 1 |
| Dec 31, 2021 | 6 | 5 | 500.00% | 5 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pelthos Therapeutics | 92 |
| Acrivon Therapeutics | 76 |
| ImmuCell | 73 |
| Neumora Therapeutics | 63 |
| Cardiff Oncology | 31 |
| Oncolytics Biotech | 29 |
| NeurAxis | 24 |
| PDS Biotechnology | 21 |
PMN News
- 1 day ago - ProMIS Neurosciences appoints Ivana Rubino as chief commercial officer - TheFly
- 1 day ago - ProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer - GlobeNewsWire
- 22 days ago - ProMIS Neurosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 27 days ago - ProMIS Neurosciences Transcript: Moody Capital Disruptive Growth & Life Science Conference - Transcripts
- 4 weeks ago - ProMIS Neurosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 5 weeks ago - ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September - GlobeNewsWire
- 6 weeks ago - ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital - TheFly
- 7 weeks ago - ProMIS Neurosciences reports Q2 EPS ($1.28), consensus ($1.90) - TheFly